Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo comparator

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,804 result(s) found for: Placebo comparator. Displaying page 18 of 91.
    «« First « Previous 14  15  16  17  18  19  20  21  22  Next» Last»»
    EudraCT Number: 2020-005756-37 Sponsor Protocol Number: CONTENTSS Start Date*: 2021-11-02
    Sponsor Name:Fundación Pública Andaluza para la Gestión de la
    Full Title: Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock
    Medical condition: Patients with septic shock who remain without reaching the hemodynamic goal of TAM> 65 mmHg, despite volume replacement and administration of noradrenaline at doses equal to or greater than 0.2 μg ...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    20.0 10021881 - Infections and infestations 10040089 Septicemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006465-38 Sponsor Protocol Number: 21EU-Fpf02 Start Date*: 2022-06-06
    Sponsor Name:IBSA Institut Biochimique S.A.
    Full Title: A Randomized, Double-Blind, Multi-Centre, Placebo-Controlled, Active Comparator Study to Evaluate the Efficacy and Safety of a diclofenac epolamine (DHEP) 2.6% medicated plaster in the treatment of...
    Medical condition: Acute pain in mild/moderate ankle sprains
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10024453 Ligament sprain PT
    23.1 10022117 - Injury, poisoning and procedural complications 10022117 Injury, poisoning and procedural complications SOC
    20.0 10022117 - Injury, poisoning and procedural complications 10028288 Muscle, tendon and ligament injuries HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000301-45 Sponsor Protocol Number: BAY94-8862/14563 Start Date*: 2011-05-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, multi-center study to assess safety and tolerability of different oral doses of BAY 94-8862 in subjects with stable chronic heart failure with left ventricular systolic...
    Medical condition: Stable chronic heart failure subjects with left ventricular systolic dysfunction and mild (Part A) or moderate (Part B) chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) DK (Completed) BE (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-004687-64 Sponsor Protocol Number: D3614C00001 Start Date*: 2019-06-17
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirm...
    Medical condition: Triple-negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) FR (Completed) CZ (Completed) ES (Ongoing) PT (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000720-18 Sponsor Protocol Number: CNTO1959PSO3002 Start Date*: 2015-02-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004368-31 Sponsor Protocol Number: I1F-MC-RHBC Start Date*: 2012-09-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A 12-Week Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psorias...
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004602-25 Sponsor Protocol Number: M04-716 Start Date*: 2005-06-30
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind,Double-Dummy, Placebo-Controlled StudyComparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects withModerate to Severe...
    Medical condition: Psoriasis Disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-024359-99 Sponsor Protocol Number: M11-891 Start Date*: Information not available in EudraCT
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects with Diabetic Neuropathic Pain
    Medical condition: Diabetic Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003616-39 Sponsor Protocol Number: 64565111OBE2001 Start Date*: 2018-04-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic S...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000114-40 Sponsor Protocol Number: CLIC477D2303 Start Date*: 2004-11-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with lithium or valproate in the treatmen...
    Medical condition: Bipolar I disorder, manic and mixed episodes DSM-IV criteria 296.0, 296.4 or 296.6
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003805-19 Sponsor Protocol Number: EFC5583 Start Date*: 2006-11-06
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredut...
    Medical condition: To evaluate the efficacy, safety and tolerability of a saredutant 100 mg dose once daily, in patients with generalized anxiety disorder.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001490-15 Sponsor Protocol Number: RIS-BMN-3001 Start Date*: 2007-04-23
    Sponsor Name:Janssen-Cilag International N.V
    Full Title: A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the...
    Medical condition: Subjects with a diagnosos of bipolar I disorder who are currently experiencing a manic or mixed episode (YMRS>20 and CGI-S>/= 4 [moderate]) or who are between mood episodes (non-acute; YMRS<12 and ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004939 Bipolar I disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004854-26 Sponsor Protocol Number: ELB245201-06 Start Date*: 2007-02-16
    Sponsor Name:elbion AG
    Full Title: A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg flupirtine (ELB245) given once daily for 12 ...
    Medical condition: Incontinent Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001138-42 Sponsor Protocol Number: CLAF237A23103 Start Date*: 2006-08-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd to Placebo as Add-On Therapy in Patients with Type 2 Diabetes I...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-005975-13 Sponsor Protocol Number: V00114 CP 201 Start Date*: 2006-04-25
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.
    Medical condition: Prospective, multicentric, international, randomised, double-blind trial in six parallel groups: 4 doses of the test product, active control and placebo. This study is intended to evaluate the ef...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000063-88 Sponsor Protocol Number: RAP-MD-31 Start Date*: 2019-03-27
    Sponsor Name:Allergan Ltd.
    Full Title: A Randomized, Double-blind, Placebo- and Active- controlled, Multicenter Study of Rapastinel as Monotherapy in Major Depressive Disorder
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-008338-35 Sponsor Protocol Number: A3921064 Start Date*: 2009-05-20
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTRE...
    Medical condition: CP 690,550 is being studied as a DMARD for the treatment of moderate to severe active RA in adults.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) GB (Completed) DK (Completed) DE (Completed) FI (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000230-34 Sponsor Protocol Number: 15906A Start Date*: 2014-09-23
    Sponsor Name:H. Lundbeck A/S
    Full Title: An interventional, randomised, double-blind, parallel-group, placebo-controlled, active-referenced (paroxetine), fixed-dose study on the efficacy of vortioxetine on cognitive dysfunction in working...
    Medical condition: Major depressive disorder and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) FI (Completed) LT (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-020839-39 Sponsor Protocol Number: RA0056Amend4 Start Date*: 2011-02-25
    Sponsor Name:UCB Biosciences, Inc
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY WITH AN ACTIVE COMPARATOR TO EVALUATE THE EFFICACY AND SAFETY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY FOR 12 WEEKS TO SUBJECTS WIT...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002322-73 Sponsor Protocol Number: I4V-MC-JADV Start Date*: 2013-01-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo- and Active Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who H...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GR (Completed) BE (Completed) LV (Completed) GB (Prematurely Ended) DE (Completed) PT (Completed) CZ (Completed) NL (Completed) LT (Completed) SK (Completed) ES (Completed) SI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 14  15  16  17  18  19  20  21  22  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 08:31:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA